ArticleInternational journal of general medicine2026
Peripheral Blood HIST1H2AE is a Candidate Epigenetic Biomarker for Coronary Artery Disease: A Multi-Dataset Discovery and Comparative Validation Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated skin-lesion transcriptomics prioritises biomarker-candidate host-response genes with pharmacological annotation in leprosy type 1 reaction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify peripheral blood biomarker candidates for coronary artery disease (CAD) and to test whether bioinformatically prioritized genes replicate in an angiography-confirmed cohort, with emphasis on HIST1H2AE as an epigenetically relevant marker. Methods: Differentially expressed genes (DEGs) were identified from three GEO datasets (GSE42148, GSE98583, GSE12288) after within-dataset normalization; DEGs were then intersected across datasets to prioritize robust candidates while avoiding direct cross-study merging and associated batch effects. Enrichment analysis and protein-protein interaction network prioritization were performed, followed by independent in silico evaluation in GSE20681 using receiver operating characteristic (ROC) analysis. HIST1H2AE and CXCL14 were then tested by qPCR in peripheral blood from 20 participants (10 angiography-confirmed CAD; 10 non-CAD controls). Immune cell proportions in GSE20681 were estimated with CIBERSORTx, and correlations with hub-gene expression were assessed. Results: Eight DEGs were consistently shared across the three discovery datasets, and HIST1H2AE and CXCL14 were prioritized as hub candidates. In GSE20681, ROC analysis suggested discriminatory ability for both genes (AUC=0.711 for HIST1H2AE; AUC=0.878 for CXCL14). In the angiography-confirmed qPCR cohort, CXCL14 was not consistently different between groups, whereas HIST1H2AE was significantly downregulated in CAD. HIST1H2AE expression showed no significant correlation with estimated immune cell proportions. Conclusion: This multi-dataset discovery and comparative validation framework prioritizes HIST1H2AE as a peripheral blood biomarker candidate for CAD with an immune-independent expression profile in the analyses performed. Given the small qPCR cohort, these findings are preliminary and require confirmation in larger, independent cohorts and mechanistic studies of chromatin-level regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.